Advanced Proteome Therapeutics Stock Net Income
| APTCFDelisted Stock | USD 0.0002 0.00 0.00% |
Fundamental analysis of Advanced Proteome allows traders to better anticipate movements in Advanced Proteome's stock price by examining its financial health and performance throughout various phases of its business cycle.
Advanced |
Advanced Proteome Therapeutics Company Net Income Analysis
Advanced Proteome's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Advanced Proteome Net Income | 759.62 K |
Most of Advanced Proteome's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Advanced Proteome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Advanced Proteome Therapeutics reported net income of 759.62 K. This is 99.78% lower than that of the Biotechnology sector and 98.92% lower than that of the Health Care industry. The net income for all United States stocks is 99.87% higher than that of the company.
Advanced Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Advanced Proteome's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Advanced Proteome could also be used in its relative valuation, which is a method of valuing Advanced Proteome by comparing valuation metrics of similar companies.Advanced Proteome is currently under evaluation in net income category among its peers.
Advanced Fundamentals
| Return On Asset | -1.07 | |||
| Current Valuation | 660.53 K | |||
| Shares Outstanding | 41.13 M | |||
| Shares Owned By Insiders | 10.53 % | |||
| Price To Earning | 2.98 X | |||
| Price To Book | 4.92 X | |||
| Gross Profit | (1.71 K) | |||
| EBITDA | 631.22 K | |||
| Net Income | 759.62 K | |||
| Cash And Equivalents | 761.6 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 227.41 K | |||
| Debt To Equity | 4.65 % | |||
| Current Ratio | 0.55 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (693.58 K) | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 11 | |||
| Beta | 1.55 | |||
| Market Capitalization | 2.47 M | |||
| Total Asset | 636.41 K | |||
| Z Score | 6.0 | |||
| Net Asset | 636.41 K |
About Advanced Proteome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Advanced Proteome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Proteome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Proteome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Advanced Pink Sheet
If you are still planning to invest in Advanced Proteome check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Advanced Proteome's history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |